Nexstim Oyj (NXTMH) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Nexstim Oyj €1.15, price €9.60, upside -88.0%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value €1.15 · Strongly overvalued (−88%)
!Quality 44/100
!Expensive Growth(revenue 5y +21.7 %/yr)
!Thin margins · 4.6% net margin (TTM)
!Moderate debt · negative free cash flow
!Mixed vs. peers(5/11)
!Moderate moat47/100
!Evidence only low, so the estimate is less certain
Watch Nexstim Oyj for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €2.18 – €16.40 · fair‑value band €0.8585 – €1.43 · the €9.60 price screens above the €1.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Nexstim in your weekly email
Every Wednesday you see whether Nexstim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
Show more
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.
Stock analysis
Nexstim Oyj (NXTMH) currently trades at €9.60, while our model-based Fair Value estimate is €1.15, implying the stock looks roughly 736.1% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €2.17 per share, and 0 of the 14 models we run sit above the €9.60 price.
Bear case: the Asset-Based group reads lowest at €0.3900, and 14 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: €0.8585 (bear) to €1.43 (bull), the price of €9.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Nexstim Oyj reported revenue of €11.0M in FY2025 versus €6.4M in FY2021, a compound +14.4%/yr. Reported net income was €573K in FY2025.
Key figures
Market cap €91.7M · P/E ratio 120.0 · P/S ratio 6.27 · EPS (TTM) €0.0800 · Net margin 5.2% · Return on equity 14.6% · Return on assets (EBIT) −3.5% · Operating margin 12.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −88%, NXTMH screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.3900 to €3.68). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €0.8585Fair Value €1.15Bull €1.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.0585 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+25.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−30.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−30.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−81% → 6%
⚠ Revenue per share shrinking 30.4%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−88% · Bottom 25%
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets3% · Above median
Net margin (TTM)5% · Above median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth13% · Above median
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (TTM)120.0× · Priciest 25%
P/B24.94× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)8.40× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)63· sector 31
PAST (return on equity)58· sector 7
HEALTH (low debt)69· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nexstim Oyj Fair Value". https://www.fairvalue-calculator.com/stock/NXTMH
Frequently asked questions
Is Nexstim Oyj (NXTMH) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €1.15 versus a price of €9.60, about −88% upside (overvalued).
What is the fair value of NXTMH?
Our model-based fair value for Nexstim Oyj is €1.15 (as of Sep 23, 2026), built from audited fundamentals. The current price: €9.60.
What is the quality score of NXTMH?
Nexstim Oyj has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nexstim Oyj (NXTMH)?
Our model-based price target is the fair value of €1.15 (as of Sep 23, 2026) from 14 valuation models. Cautious scenario €0.8585, optimistic scenario €1.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Nexstim Oyj stock forecast for 2026?
Our models put fair value at €1.15, about −88% upside versus a price of €9.60 (overvalued). Cautious scenario €0.8585, optimistic scenario €1.43. The calculation is refreshed regularly with new filings.
What is the revenue of Nexstim Oyj (NXTMH)?
Nexstim Oyj reported trailing-twelve-month revenue of about €12.4M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Nexstim Oyj (NXTMH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nexstim Oyj it is €1.15 per share (as of Sep 23, 2026), against a price of €9.60. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Nexstim Oyj stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NXTMH trades above its calculated fair value: price €9.60, fair value €1.15, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NXTMH?
No. The price is what the market pays today (€9.60); the fair value is what the company's own numbers justify (€1.15). For Nexstim Oyj the two are €8.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nexstim Oyj worth?
The market values Nexstim Oyj at about €91.7M (market capitalisation, as of Sep 23, 2026). Per share that is €9.60; our models calculate a fair value of €1.15 per share.
What do the bullish and bearish scenarios say about NXTMH?
Our models span a range for Nexstim Oyj: cautious scenario €0.8585, base €1.15, optimistic €1.43 per share (as of Sep 23, 2026, price €9.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NXTMH?
Nexstim Oyj trades at a price-to-earnings ratio of 120.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.15 is built from several models across several years. Other multiples: P/B 24.9, P/S 8.4.
How solid is the balance sheet of Nexstim Oyj (NXTMH)?
Balance-sheet figures for Nexstim Oyj (as of Sep 23, 2026): return on equity 14.6%, debt of 0.61 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is NXTMH from its 52-week high?
Nexstim Oyj trades at €9.60, about 41% below its 52-week high of €16.40 and 18% above the low of €8.14 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €1.15 is for.
Which stocks are comparable to Nexstim Oyj?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nexstim Oyj stock attractive at the current price?
The data as of Sep 23, 2026: price €9.60, calculated fair value €1.15 (−88%), Quality Score 44/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NXTMH calculated?
We run Nexstim Oyj through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €1.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Nexstim Oyj itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nexstim Oyj (NXTMH)?
The closing price on Sep 24, 2026 was €9.60. Our model-based fair value is €1.15, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nexstim Oyj right now?
The price sits above even our optimistic bull case (€1.43). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Nexstim Oyj
How large is the market capitalisation of Nexstim Oyj (NXTMH)?
The market capitalisation of Nexstim Oyj is €91.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nexstim Oyj (NXTMH)?
The price-to-sales ratio of Nexstim Oyj is 6.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nexstim Oyj (NXTMH)?
Earnings per share at Nexstim Oyj are €0.0800 (price ÷ EPS = P/E 120.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nexstim Oyj (NXTMH)?
The net margin of Nexstim Oyj is 5.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nexstim Oyj (NXTMH)?
The return on equity (ROE) of Nexstim Oyj is 14.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nexstim Oyj (NXTMH)?
On an EBIT basis the return on assets of Nexstim Oyj is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nexstim Oyj (NXTMH)?
The operating margin of Nexstim Oyj is 12.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nexstim Oyj (NXTMH)?
Revenue at Nexstim Oyj is growing +12.5% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nexstim Oyj (NXTMH)?
Earnings per share at Nexstim Oyj are growing +822% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nexstim Oyj (NXTMH) generate?
The free cash flow of Nexstim Oyj is −€37.3K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nexstim Oyj (NXTMH) carry?
The net debt of Nexstim Oyj is €1.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nexstim Oyj in the live analysis
One click puts Nexstim Oyj on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
